Mutated gp41 Peptide for HIV-1 Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV antibody detection methods face challenges in sensitivity and specificity, particularly in early stage HIV-1 infection diagnosis, leading to potential false negatives and false positives, and are costly due to equipment and reagent requirements.
Innovation Solution
A synthetic peptide with specific amino acid mutations at sites T77, N101, G105, P124, and K127, offering high sensitivity and specificity for detecting HIV-1 antibodies, reducing false results and improving early stage detection capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional HIV antibody detection methods are used, then equipment and reagents can be provided for testing, but sensitivity and specificity are insufficient leading to false negatives and false positives
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the detection peptide. Specifically, it uses a mutated gp41 peptide sequence (with mutations at positions 77, 101, 105, 124, and 127) instead of the wild-type sequence. These parameter changes in the peptide structure enable the detection method to achieve 100% sensitivity and 99.75% specificity, resolving the contradiction between measurement precision and reliability by optimizing the molecular recognition parameters.
2Measurement precision
If HIV antigen and nucleic acid testing are implemented, then more accurate detection can be achieved, but equipment, reagents, and labor costs become excessive
Solution Approach 1:
The patent employs a simplified peptide-based detection system that eliminates the need for complex nucleic acid extraction equipment and reagents. By using a synthetic peptide conjugate as the detection target, the method achieves high accuracy through a simpler immunological assay format, reducing device complexity while maintaining measurement precision.
Solution Approach 2:
The patent extracts only the essential immunogenic component (the gp41 peptide sequence) from the complete viral structure. By isolating and utilizing specifically the mutated gp41 peptide region that elicits strong antibody responses, the method achieves accurate detection without requiring the complex equipment and reagents needed for full antigen or nucleic acid testing.
3Reliability
If conventional detection peptides are used, then detection can be performed, but sensitivity is insufficient for early stage HIV-1 infection diagnosis
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations at five key positions (77, 101, 105, 124, 127) in the gp41 peptide sequence. These parameter changes optimize the peptide's conformational structure and antigenic determinants, enabling it to bind more effectively to early-stage HIV antibodies. This results in 100% sensitivity for detecting anti-HIV-1 antibodies, including those present in early infection when antibody levels are low.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthetic peptide achieves 100% sensitivity and specificity greater than 99.75%, enhancing the accuracy of HIV-1 antibody detection and facilitating early diagnosis of HIV-1 infection and AIDS.
Implementation Method 1
The synthetic peptide has reactinogenicity of binding to HIV-1 type antibodies
Data Source
AI summary
The present disclosure relates to the field of medical diagnosis, and specifically, relates to a synthetic peptide for detecting HIV-1. The synthetic peptide is obtained by mutating the amino acid sequence set forth as SEQ ID NO: 1. The synthetic peptide can better detect anti-HIV-1 antibodies, and can better avoid potential “false negative” and “false positive” results.